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Macrophage migration inhibitory factor (MIF) is a proinﬂammatory cytokine that may play a role in the pathogenesis of inﬂam-
mation. Radiolabeled anti-MIF McAb can be used to detect in vivo inﬂammatory changes. The objective of this study was to
investigate in vivo biology of radioiodinated anti-MIF McAb using the inﬂammation model mice. Anti-MIF McAb was radioiod-
inated with Na125I by Iodogen method. Animal models were induced in the mice by intramuscular injection of S. aureus, E. coli,
and turpentine oil. The biodistribution studies with radioiodinated anti-MIF McAb were performed on inﬂammation mice. The
relationship between inﬂammatory lesions and anti-MIF McAb binding was investigated using the percent of injected dose per
gram tissue (% ID/g) of tissue samples and whole-body autoradiography. The radioactivity of 125I-anti-MIF McAb in the inﬂam-
matory tissue increased gradually for three inﬂammation models. The highest uptake was found in S. aureus group and the lowest
was in E. coli group. The uptake in turpentine oil group was average. Whole-body autoradiography showed that all inﬂammation
foci could be visualized clearly from 24 hours after injection, but 48 hours images were much clearer in accordance with the high
T/NT ratio. These results demonstrate the ability of radioiodinated anti-MIF McAb to measure in vivo inﬂammatory events rep-
resented by high expression of MIF and suggests that radiolabeled anti-MIF McAb warrants further investigation as a potential
inﬂammation-seeking agent for imaging to detect inﬂammatory disorders.
Copyright © 2007 Chao Zhang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Macrophage migration inhibitor factor (MIF) was originally
discovered as a kind of lymphokines involved in delayed type
hypersensitivity and various macrophage functions [1–3].
However, its descriptive name was shown to be rather im-
p r e c i s ea sM I Fc a na l s op r o m o t em a c r o p h a g er o l l i n ga n d
transmigration by upregulating P-selection expression in en-
dothelial cells lining the site of inﬂammation [4, 5]. Numer-
ous animal studies have revealed the critical role of MIF in
acute and chronic inﬂammation [6, 7]. The increased levels
of MIF in certain pathological conditions may be indicative
of its involvement in those diseases. Indeed, increased MIF
plasma or serum levels were identiﬁed in patients with severe
sepsis [8], Crohn’s disease and ulcerative colitis [9], acute
pancreatitis [10], rheumatoid arthritis (RA) [11], type 2 di-
abetes (T2D) [12], Guillain-Barre syndrome [13], or multi-
ple sclerosis [14]. Consequently, MIF’s activity has become a
potential target for treating these various disorders. In this
study, we labeled anti-MIF monoclonal antibody (McAb)
with radioiodine Na125I and investigated its biodistribution
and pharmacokinetics in vivo in animal models with inﬂam-
mation.
2. MATERIALS AND METHODS
2.1. Radioiodinationofanti-MIFMcAb
All commercially available chemicals were of analytic grade
and anti-MIF McAb (R&D Systems) was pharmaceutical
grade. Anti-MIF McAb was iodinated with Na125I (speciﬁc
activity 37MBq/mg, China Institute of Atomic Energy) us-
ingtheIodogentechnique(Pierce).Radioiodinatedantibody
was separated from free iodine using a size exclusion column
(SephadexG-25,Pharmacia).Thespeciﬁcactivityofradioio-
dinated antibody is 29.56GBq/μmol. The radiochemical pu-
rity is >95% (paper chromatography).
2.2. Preparationofinﬂammationanimalmodel
The animal experiments were carried out in accordance
with institutional, national, and international guidelines for2 Mediators of Inﬂammation
humane use of animals for research. Fourty eight mice
(BALB/c, 18 ∼ 22g, Animal Center of Shandong Univer-
sity) were divided into three groups, each group consisting
of 16 mice, respectively. The ﬁrst and second groups were in-
ducedinﬂammationbyintramuscularlyinjecting2×107–108
colonyforming units (CFU)of S.aureusandE.coliin0.2mL,
respectively, into the left thigh muscle [15]. The third group
of mice were induced sterile inﬂammation by intramuscular
injectionof0.2mLturpentineoil[15].Twentyfourhoursaf-
ter inoculation, focal inﬂammation occurred. Those inﬂam-
mation models were proved by histological studies (data not
showed).
2.3. Biodistributionof 125I-anti-MIFMcAb
Mice with the left thigh inﬂammation were intraperitoneally
injected with 3.7MBq 125I-anti-MIF McAb in 0.2mL PBS.
Three mice of each group were sacriﬁced by cervical disloca-
tion at 30 minutes, 4 hours, 24 hours, 48 hours, and 72 hours
after injection, respectively. A sample of 1mL blood was
collected at the time of decapitation. Samples of two thigh
muscles (left as target, right as control), lungs, heart, liver,
spleen, kidney, and bone were removed and weighted. The
tissue radioactivity was measured with a wipe test counter
(CAPRAC). The percent of injected dose per gram tissue (%
ID/g)wascalculatedbycomparisonwithsamplestostandard
dilutions of the initial dose.
2.4. Whole-bodyautoradiography
Three groups of mice inﬂammatory models were established
by the same method like biodistribution study. Each group
consists of 4 mice. 125I-anti-MIF McAb (3.7MBq in 0.2mL
PBS) were injected intravenously via the tail vein. Serial im-
ageswereperformedat24hours,48hours,and72hoursafter
injection. The anesthetized mice were placed on the storage-
phosphor screen plate with the ventral side facing the plate,
in subdued light. The plate was exposed to a mouse for 45
minutes. At cessation of exposure, the plate was immediately
covered with an opaque plastic sheet, then transferred to the
scanner, and scanned by typhoon trio + (laser red 633nm,
pixel size 200 mcrons, phosphor mode: best sensitivity).
2.5. Statistics
Dates were expressed as the x ± s. The dates were analyzed
using SPSS11.0 software.
3. RESULTS
3.1. Antibodyclearancefromtheblood
125I-anti-MIF McAb shortly transited from the peritoneal
cavity to the circulation after intraperitoneal injection. At
ﬁrst 30 minutes, the activity of 125I-anti-MIF McAb in the
blood increased rapidly up to 45.00% ID, 36.66% ID, and
45.66% ID, respectively, in S. aureus, E. coli, and turpentine
group. Then, it went up and reached a zenith at 4 hours post
injection.Levelswere60.03%ID,38.59%ID,and54.42%ID,
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Figure 1: Clearance of 125I-anti-MIF McAb from the blood in S.
aureusgroup,E.coligroup,andturpentineoilgroup(%ID/g,x±s).
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Figure 2: Accumulation of 125I-anti-MIF McAb in the inﬂamma-
torytissueofS.aureusgroup,E.coligroup,andturpentineoilgroup
(% ID/g, x ±s).
respectively, in three groups. After that point, the activity in
the blood went down quickly (Figure 1).
3.2. Accumulationintheinﬂammatorytissue
The concentration of 125I-anti-MIF McAb in the inﬂamma-
torytissuewasexpressedasapercentageoftheinitialdose(%
ID/g,Figure 2)andT/NT(target/nontarget)ratio(Figure 3).
The activity of 125I-anti-MIF McAb in the inﬂammatory tis-
sue increased gradually for three inﬂammation models. The
highest uptake was S. aureus group and the lowest was E. coli
g r o u p .T h eu p t a k eo ft u r p e n t i n eo i lg r o u pw a sa v e r a g e .I na l l
three groups, T/NT was >3 at 4 hours post injection and in-
creasedcontinuallyinthewholeobservedperiod:T/NTratio
was >7a t4 8h o u r sa n d>9a t7 2h o u r s .Chao Zhang et al. 3
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Figure 3: Change of T/NT in the S. aureus, E. coli, and turpentine
oil group.
3.3. Biodistributionof 125I-anti-MIFMcAb
As expected, the biodistribution of 125I-anti-MIF McAb
showed the highest uptake and the lowest decrease in the in-
ﬂammatory tissue. The activity in the blood was higher than
thekidney, liver,spleen,heart,andlung.Thechangeofactiv-
ity in the heart and lung was the same as blood. Peak uptake
inthekidney(0.2575±0.1640%ID/g,0.2452±0.0612%ID/g,
and 0.2909 ± 0.0856% ID/g, respectively, in the S. aureus,
E. coli, and turpentine oil group), liver (0.2271 ± 0.1345%
ID/g,0.1682±0.0028% ID/g,and0.1828±0.0955% ID/g,re-
spectively in the S. aureus, E. coli, and turpentine oil group),
spleen (0.1450 ± 0.1621% ID/g, 0.0882 ± 0.0799% ID/g,
0.1704 ± 0.1351% ID/g, respectively in the S. aureus, E. coli,
and turpentine oil group) occurred around 30 minutes, fol-
lowed by gradual clearance over time. This indicated that the
product of 125I-anti-MIF McAb was excreted from kidney or
swallowed by reticuloendothelium of liver and spleen, result-
ing in deiodination.
3.4. Imagingoftheinﬂammatoryfoci
Whole-body autoradiography showed that all inﬂammation
foci could be visualized clearly from 24 hours after injection,
but after 48 hours images were much clearer in accordance
with the high T/NT ratio (Figures 4, 5,a n d6). The radioac-
tivity was the highest in S. aureus lesion, average in turpen-
tine lesion, and the lowest in E. coli lesion.
4. DISCUSSION
The diagnosis of inﬂammatory processes is an important
goalinmedicine.Insomecasesthediagnosisiseasy,basedon
the clinical history and the physical examination of patient.
Other cases are more diﬃcult to diagnose because they are
asymptomatic or with nonspeciﬁc symptoms. Thus, nuclear
medicine provides several techniques for in vivo detection of
inﬂammatory processes. An expanding and even more inter-
esting ﬁeld of modern nuclear medicine is the development
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Figure 4: Serial images of S. aureus group at diﬀerent times: the left
thigh inﬂammation foci accumulated much more radioactivity of
125I-anti-MIF McAb; the highest was at 48hours.
of radiolabelled receptor ligands, able to bind in vivo to spe-
ciﬁc receptors, allowing the noninvasive detection of speciﬁc
cells and tissues.
Over the last decades, the imaging agents for inﬂamma-
tion have been developed rapidly: from nonbioactive chemi-
cals to bioactive cell, and from macromolecule and antibody
segments to peptides [16–20], and so on. Amongst the spe-
ciﬁc tracers, a new class of radiopharmaceuticals is repre-
sented by monoclonal antibodies (MoAb) [21–23]. The use
ofantibodiesagainstsurfacegranulocyteorlymphocyteanti-
gens may improve the ability to detect inﬂammatory pro-
cesses compared to the use of radiolabeled leukocytes.
The inﬂammatory response is rapid and includes secre-
tion of cytokines and proinﬂammatory mediators that can
induce an inﬂammatory response. MIF is believed to initiate
inﬂammationbyreleaseofanumberofproinﬂammatorycy-
tokines including TNF-α, interleukin(IL)-1β, and IL-6, and
tobeimplicatedintheactivationofTcellsandmacrophages.
RecentreevaluationofMIFhassuggestedthatMIFmaybean
important mediator of various inﬂammatory diseases, neu-
tralization of MIF with either anti-MIF antibody or chemi-
cally derived inhibitors of MIF’s enzymatic activity could be
a valuable tool for treatment of various inﬂammatory disor-
ders [24, 25].
In this study, we use the radioiodinated anti-MIF McAb
to evaluate in vivo biology of MIF with the inﬂammation an-
imal model in the BALB/c mice. Biodistribution studies of4 Mediators of Inﬂammation
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Figure 5: Serial images of turpentine group at diﬀerent times: the
left thigh inﬂammation lesion accumulated more radioactivity of
125I-anti-MIF McAb and was visualized clearly.
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Figure 6: Serial images of E. coli group at diﬀerent times: after 48
hours image of the left thigh inﬂammation foci was clear, but the
amount of radioactivity was less than S. aureus or turpentine lesion.
125I-anti-MIF McAb in animals with S. aureus, E. coli,a n d
turpentine oil inﬂammation indicated speciﬁc uptake in in-
ﬂammatory tissues: T/NT was >3a t4h o u r sp o s ti n j e c t i o n
and increased continually up to >7a t4 8h o u r sa n d>9a t7 2
hours. High uptake in the kidney, liver, and spleen reﬂected
that the product of 125I-anti-MIF McAb was excreted from
kidney or swallowed by reticuloendothelium of liver and
spleen, resulting in deiodination. Furthermore, serial images
of whole-body autoradiography of 125I-anti-MIF McAb also
demonstrated clear delineation of the inﬂammatory foci. All
foci of the inﬂammation could be visualized clearly from 24
hours post injection.
This study demonstrates the ability of radioiodinated
anti-MIF McAb to measure in vivo inﬂammatory events rep-
resented by high expression of MIF and suggests that radi-
olabeled anti-MIF McAb warrants further investigation as a
potential inﬂammation-seeking agent for imaging to detect
inﬂammatory disorders.
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